CD274 and cancer: Consistent with a role of activated T-cells in HEV neogenesis, combining anti-angiogenic therapy with anti-PD-L1 immunotherapy was sufficient to induce HEVs in several orthotopic and genetically engineered mouse models of cancer, stimulating tumor immunity [332].